Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh Ellis

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 25, 2012
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cellsRosalba Minelli, Roberta Cavalli, Leigh Ellis, et al.
Frontiers in Bioscience (Elite Edition)|March 23, 2023
Targeting Glutamine Metabolism in Prostate CancerNeil Bhowmick, Edwin Posadas, Leigh Ellis, et al.
Cancer Immunology Research|October 21, 2017
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T CellsBrian M Olson, Melissa Gamat, Joseph Seliski, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Drugs|February 17, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?Jacob J Adashek, Joshua J Breunig, Edwin Posadas, et al.
Oncotarget|May 12, 2015
Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migrationAo Zhang, Masahiro Hitomi, Noah Bar-Shain, et al.
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 12, 2020
Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate CancerDeborah L Burkhart, Katherine L Morel, Kristine M Wadosky, et al.
Nature Reviews. Urology|November 14, 2023
Genetic and biological drivers of prostate cancer disparities in Black menJun Gong, Daniel M Kim, Michael R Freeman, et al.
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 25, 2012
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cellsRosalba Minelli, Roberta Cavalli, Leigh Ellis, et al.
Frontiers in Bioscience (Elite Edition)|March 23, 2023
Targeting Glutamine Metabolism in Prostate CancerNeil Bhowmick, Edwin Posadas, Leigh Ellis, et al.
Cancer Immunology Research|October 21, 2017
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T CellsBrian M Olson, Melissa Gamat, Joseph Seliski, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Drugs|February 17, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?Jacob J Adashek, Joshua J Breunig, Edwin Posadas, et al.
Oncotarget|May 12, 2015
Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migrationAo Zhang, Masahiro Hitomi, Noah Bar-Shain, et al.
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 12, 2020
Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate CancerDeborah L Burkhart, Katherine L Morel, Kristine M Wadosky, et al.
Nature Reviews. Urology|November 14, 2023
Genetic and biological drivers of prostate cancer disparities in Black menJun Gong, Daniel M Kim, Michael R Freeman, et al.
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
Pageof 7